Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

[Proteasome inhibitors: from early stages to future prospects].

Mita N, Murata S.

Nihon Rinsho. 2012 Nov;70 Suppl 8:84-90. Japanese. No abstract available.

PMID:
23513817
2.

[Development and clinical application of novel proteasome inhibitors].

Iida S.

Rinsho Ketsueki. 2012 Apr;53(4):417-25. Review. Japanese. No abstract available.

PMID:
22687975
3.

The ubiquitin-proteasome-system.

Sommer T, Wolf DH.

Biochim Biophys Acta. 2014 Jan;1843(1):1. doi: 10.1016/j.bbamcr.2013.09.009. Epub 2013 Sep 19. No abstract available.

4.

[Proteasome inhibitor].

Yagi H.

Nihon Rinsho. 2014 Jun;72(6):1125-9. Review. Japanese.

PMID:
25016815
5.

An historic perspective of proteasome inhibition.

Esseltine DL, Mulligan G.

Semin Hematol. 2012 Jul;49(3):196-206. doi: 10.1053/j.seminhematol.2012.04.009. Review.

PMID:
22726542
6.

Discovery and development of second-generation proteasome inhibitors.

Kirk CJ.

Semin Hematol. 2012 Jul;49(3):207-14. doi: 10.1053/j.seminhematol.2012.04.007. Review.

PMID:
22726543
7.

[Proteasome inhibitors--new option in the treatment of tumor diseases].

Spicka I, Klener P.

Cas Lek Cesk. 2004;143(10):701-4. Czech.

PMID:
15584622
8.

Proteotoxic stress targeted therapy (PSTT).

Sherman MY.

Oncotarget. 2011 May;2(5):356-7. No abstract available.

9.

Proteasome inhibition in transplantation-focusing on the experience with bortezomib.

Liang Y, Liu H.

Curr Pharm Des. 2013;19(18):3299-304. Review.

PMID:
23151133
10.

Novel proteasome inhibitors to overcome bortezomib resistance.

Ruschak AM, Slassi M, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Epub 2011 May 23. Review.

11.

Proteasome inhibition as a therapeutic strategy for hematologic malignancies.

Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC.

Expert Rev Anticancer Ther. 2005 Jun;5(3):465-76. Review.

PMID:
16001954
12.

The proteasome as a potential target for novel anticancer drugs and chemosensitizers.

Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B, Dou QP.

Drug Resist Updat. 2006 Dec;9(6):263-73. Epub 2007 Jan 2. Review.

PMID:
17197231
13.

[Proteasome inhibitor].

Yamamura M, Hirai T, Yamaguchi Y.

Nihon Rinsho. 2010 Jun;68(6):1079-84. Review. Japanese.

PMID:
20535959
14.

Productively combining proteasome inhibition with the immunotherapy of cancer.

Sayers T.

J Mol Med (Berl). 2008 Aug;86(8):857-60. doi: 10.1007/s00109-008-0384-5. No abstract available.

15.

Proteasome inhibition for antibody-mediated allograft rejection.

Sadaka B, Alloway RR, Shields AR, Schmidt NM, Woodle ES.

Semin Hematol. 2012 Jul;49(3):263-9. doi: 10.1053/j.seminhematol.2012.04.008. Review.

PMID:
22726550
16.

[Proteasome inhibitors in treatment of multiple myeloma].

Kubiczková L, Matějíková J, Sedlaříková L, Kryukov F, Hájek R, Sevčíková S.

Klin Onkol. 2013;26(1):11-8. Review. Czech.

PMID:
23528167
17.

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G.

Blood. 2008 Mar 1;111(5):2765-75. Epub 2007 Dec 5.

18.

New agents for the treatment of lymphoma.

Stathis A, Ghielmini M.

Ann Oncol. 2012 Sep;23 Suppl 10:x92-8.

PMID:
22988000
19.
20.

Ubiquitin and cancer: from molecular targets and mechanisms to the clinic -- AACR Special Conference.

Colland F.

IDrugs. 2006 Mar;9(3):179-81. No abstract available.

PMID:
16523381
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk